HUTCHMED (HCM) announces, following negotiations with the China National Healthcare Security Administration, ORPATHYS has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic non-small cell lung cancer adult patients with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy. The updated NRDL will take effect from March 1, 2023. Savolitinib, marketed in China under the brand name ORPATHYS, is an oral, potent and highly selective MET tyrosine kinase inhibitor jointly developed by AstraZeneca (AZN) and HUTCHMED with HUTCHMED taking the lead in China, and commercialized by AstraZeneca worldwide.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCM:
- HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
- Hutchmed completes patient enrollment for ESLIM-01 trial
- HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
- Hutchmed initiates filing of rolling submission of fruquintinib NDA
- HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
